Articles

ANVISA Regulatory Changes: Impact on Foreign Pharma Expedited Approvals

Discover how recent ANVISA regulatory changes affect expedited approvals for foreign pharmaceutical companies, streamlining access to essential medications.

Biosimilar Regulation Japan: Aligning PMDA with EMA and FDA Guidelines

This article examines Japan's biosimilar regulations, focusing on how the PMDA aligns with EMA and FDA guidelines to enhance the approval process for drugs like infliximab.

Saudi Arabia National Cancer Registry: Trends & Oncology Treatment Insights

The Saudi Arabia National Cancer Registry reveals significant trends in cancer incidence and treatment, highlighting advancements in therapies such as Pembrolizumab for improved patient outcomes.

Radiotherapy in African Cancer Centers: Current Status & Expansion Plans 2024

This article discusses the advancements and expansion plans for radiotherapy in African cancer centers, highlighting the need for improved cancer treatment options.

SAHPRA Biosimilars Approval: Trends and Impact on Affordable Medicine Access

This article delves into SAHPRA's recent biosimilars approvals, highlighting trends and their significant role in enhancing access to affordable medications.

SAHPRA accelerated approval oncology: What You Need to Know

Learn about SAHPRA's accelerated approval process for oncology, which expedites access to essential cancer treatments, including Pembrolizumab.

Pandemic Trial Networks Repurposed: Africa’s COVID-19 Legacy in Clinical Research

This article examines the impact of Africa's COVID-19 pandemic trial networks on future clinical research, highlighting innovative strategies and drug development.

Leukemia Treatment GCC: CAR-T and Blincyto Adoption Challenges 2026

This article delves into the adoption challenges of CAR-T and Blincyto in leukemia treatment within the GCC, highlighting key insights for 2026.

SAHPRA Approval Trastuzumab Deruxtecan: What You Need to Know

SAHPRA has approved Trastuzumab Deruxtecan, a groundbreaking therapy for HER2-positive breast cancer, offering new hope for patients.

HIV Clinical Trials Africa: IMPALA Trial Validates CAB/RPV LA Efficacy

The IMPALA trial confirms the efficacy of CAB/RPV LA in treating HIV, showcasing its potential to improve patient care in Africa.

Pembrolizumab Combinations Mexico: COFEPRIS Market Access & Clinical Insights

Discover the latest on Pembrolizumab combinations in Mexico, including COFEPRIS market access and vital clinical insights for enhanced cancer therapies.

ANVISA Approves Trastuzumab Deruxtecan: What You Need to Know

Trastuzumab Deruxtecan has been approved by ANVISA for the treatment of HER2-positive breast cancer, offering new hope for patients and healthcare providers.

SFDA expedited review programs: Impact on innovative oncology drug approvals

This article examines the impact of SFDA expedited review programs on the approval process for innovative oncology drugs, enhancing patient access to treatments.

ANVISA Approves Emtricitabine + Tenofovir Fumarate: Market Impact in Brazil

The recent ANVISA approval of Emtricitabine + Tenofovir Fumarate marks a pivotal moment for HIV treatment options in Brazil, influencing market dynamics.

Pfizer AI Strategy: Driving Pharma Innovation and Dominance

Discover how Pfizer’s AI strategy is transforming pharmaceutical R&D, accelerating drug discovery, optimizing clinical trials, and reinforcing its leadership in the pharma industry, with a focus on the APAC region.

AI Drug Discovery Patent Rankings 2025: Deep EigenMatics Leads Globally

Deep EigenMatics has topped the 2025 AI drug discovery patent rankings, outpacing major pharma globally. Discover how AI is reshaping pharmaceutical innovation.

AI-Driven Drug Discovery Partnership: Merck and Mayo Clinic Lead Innovation

Merck and the Mayo Clinic have launched a groundbreaking AI-driven drug discovery partnership. This collaboration aims to revolutionize pharmaceutical research by integrating artificial intelligence and clinical expertise to speed up new drug development.

Pharma Supercomputer: Eli Lilly and NVIDIA’s AI-Powered Breakthrough

Eli Lilly and NVIDIA have partnered to build the pharmaceutical industry's most powerful supercomputer. This AI-driven innovation aims to accelerate drug discovery and development, enhancing computational research capabilities globally.

Merck Mayo Clinic AI Partnership: Advancing Drug Discovery

Merck and the Mayo Clinic have joined forces to leverage AI in accelerating drug discovery and development. This partnership combines Merck's expertise with Mayo Clinic's research capabilities to transform pharmaceutical innovation.

African Medicines Agency: Harmonizing Regulatory Standards to Boost Pharma Access

The African Medicines Agency aims to streamline regulatory processes, improving access to vital medications such as antiretrovirals and boosting public health across Africa.